Increased Serine and One-Carbon Pathway Metabolism by PKC?/? Deficiency Promotes Neuroendocrine Prostate Cancer.

ABSTRACT: Increasingly effective therapies targeting the androgen receptor have paradoxically promoted the incidence of neuroendocrine prostate cancer (NEPC), the most lethal subtype of castration-resistant prostate cancer (PCa), for which there is no effective therapy. Here we report that protein kinase C (PKC)?/? is downregulated in de novo and during therapy-induced NEPC, which results in the upregulation of serine biosynthesis through an mTORC1/ATF4-driven pathway. This metabolic reprogramming supports cell proliferation and increases intracellular S-adenosyl methionine (SAM) levels to feed epigenetic changes that favor the development of NEPC characteristics. Altogether, we have uncovered a metabolic vulnerability triggered by PKC?/? deficiency in NEPC, which offers potentially actionable targets to prevent therapy resistance in PCa.

SUBMITTER: Reina-Campos M 

PROVIDER: S-EPMC6424636 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature